The Addario Lung Cancer Medical Institute (ALCMI) Names Steven W.
Young, President
SAN FRANCISCO, Calif. (Business Wire EON/PRWEB ) September 29, 2008 --
The Addario Lung Cancer Medical Institute (ALCMI) today announced the
appointment of Steven W. Young to the position of president. In this
role, Young will develop organizational strategy and provide leadership,
vision, and direction. Tony Addario, formerly the President of ALCMI,
has assumed the role of Chief Executive Officer.
“Mr. Young has exceptional experience in
establishing and directing disease-centric pre-clinical and clinical
discovery, and drug development models in collaboration with
investigators in the academic, community and biopharmaceutical settings,”
said Addario. “His appointment represents
precisely the kind of opportunity to jumpstart research that led us to
establish the Bonnie J. Addario Lung Cancer Foundation (BJALCF) in 2006
and ALCMI in 2008.”
Young has nearly 20 years experience in laboratory and clinical research
and most recently served as the inaugural Executive Director of the
Multiple Myeloma Research Consortium (MMRC), founded by myeloma patient
Kathy Giusti. Prior to his position with the MMRC, Young directed the
development and successful launches of several clinical research
for-profit business models and was the administrative director of
NIH-funded General Clinical Research Centers at Mount Sinai School of
Medicine and Cornell University College of Medicine.
“There has been little to no movement in the
survival rate of Lung Cancer in the last half century,”
said David Jablons, M.D., University of California, San Francisco, and
co-founder of BJALCF. “Everyone will say I’m
the ultimate optimist, but I really do think that in some finite period
in our lifetime, especially now with ALCMI, we will see Lung Cancer, if
not completely eradicated, then dramatically changed in its impact on
life.”
BJALCF has committed to identifying startup funding for its
translational-focused sister organization, ALCMI (pronounced “alchemy”).
The goal of ALCMI is to significantly improve Lung Cancer patient
outcomes and survival. ALCMI accomplishes this mission by directly
facilitating scientific efforts to better characterize this complex and
virtually fatal disease and thus accelerate the development of new,
targeted therapies that will lead to treatments tailored to the
individual Lung Cancer patient. To this end, ALCMI will work with its
partners and supporters to establish a centralized, high-quality
tissue/data bank, with investigators subsequently utilizing the
resultant findings in ALCMI clinical trials to screen and enrich for
patients who have the best chance to positively respond to the study
drugs.
“Grateful to be in remission, I spend most of
my time trying to change the way Lung Cancer is diagnosed, researched,
and treated,” said Bonnie J. Addario, Lung
Cancer survivor and founder and president of BJALCF. “Having
Steven join our team is going to take us to the next level and beyond in
accomplishing our goals and ultimately increasing the survival rate for
Lung Cancer.”
Lung Cancer Facts
According to National Cancer Institute (NCI) estimates, there will be
over 215,000 new Lung Cancer cases. More than 160,000 people —
smokers, former smokers, and non-smokers —
will die of Lung Cancer in the U.S. in 2008. That is more people than
the combined total of the next four biggest cancer killers: colon cancer
(49,960 deaths), breast cancer (40,930 deaths), pancreatic cancer
(34,290 deaths), and prostate cancer (28,660 deaths).
The overall 5-year relative survival rate of Lung Cancer for 1996-2004
from 17 SEER (Surveillance Epidemiology and End Results) geographic
areas was 15.2%. Based on rates from 2003-2005, 1 out of 14 men and
women will be diagnosed with cancer of the lung and bronchus during his
or her lifetime.
Worldwide, an estimated 1.5 million new cases were expected in 2007,
accounting for 12% of total cancer diagnoses. Lung Cancer is the leading
cause of cancer death in men and the second leading cause of cancer
death in women, with about 975,000 men and 376,000 women projected to
die from it in 2007.
About ALCMI
Lung Cancer survivor Bonnie J. Addario established the Addario Lung
Cancer Medical Institute (ALCMI) in 2008 as a 501(c)(3) non-profit
organization that accelerates the discovery, development, and delivery
of new and more effective diagnostic and treatment options for patients
in need. The goal of ALCMI is to significantly improve Lung Cancer
patient outcomes and survival. This will be accomplished by driving the
rapid development and study of new, targeted therapies that will lead to
individualized therapies for Lung Cancer patients.
About Bonnie J. Addario Lung Cancer Foundation (BJALCF)
BJALCF is one of the nation’s largest
philanthropies devoted exclusively to eradicating Lung Cancer through
research, early detection, education, prevention, and treatment. The
Foundation works with a diverse group of physicians, organizations,
individuals, and survivors to identify solutions and make timely and
meaningful change. BJALCF was established in 2006 as a 501(c)(3)
non-profit organization and has raised over $3 million for Lung Cancer.
For more information, please visit: www.lungcancerfoundation.org.
See the original story at: http://eon.businesswire.com/releases/lung_cancer/addario_lung/prweb1402464.htm
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/RW1wdC1JbnNlLUluc2UtSW5zZS1IYWxmLVNpbmctWmVybw==
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
